![Ulrich Kalinke](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ulrich Kalinke
Chief Executive Officer at Twincore, Zentrum für Experimentelle und Klinische
Ulrich Kalinke active positions
Companies | Position | Start | End |
---|---|---|---|
Twincore, Zentrum für Experimentelle und Klinische
![]() Twincore, Zentrum für Experimentelle und Klinische Miscellaneous Commercial ServicesCommercial Services Twincore, Zentrum für Experimentelle und Klinische, is a research institute based in Hannover, Germany. Twincore specializes in translational infection research, with a focus on viral infections, respiratory infections, and organ-specific immunity and metabolism research. The German company also conducts pre-clinical and clinical studies on vaccines and antiviral antibodies. Twincore has an international team of over 40 scientists from more than 20 nations, and the private company places a strong emphasis on international collaboration and exchange programs. The company has organized several symposiums and publishes research papers on various topics related to infection research. The company was founded in 2008, and the CEO is Ulrich Kalinke. | Chief Executive Officer | - | - |
Career history of Ulrich Kalinke
Statistics
International
Germany | 2 |
Operational
Chief Executive Officer | 1 |
Sectoral
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Twincore, Zentrum für Experimentelle und Klinische
![]() Twincore, Zentrum für Experimentelle und Klinische Miscellaneous Commercial ServicesCommercial Services Twincore, Zentrum für Experimentelle und Klinische, is a research institute based in Hannover, Germany. Twincore specializes in translational infection research, with a focus on viral infections, respiratory infections, and organ-specific immunity and metabolism research. The German company also conducts pre-clinical and clinical studies on vaccines and antiviral antibodies. Twincore has an international team of over 40 scientists from more than 20 nations, and the private company places a strong emphasis on international collaboration and exchange programs. The company has organized several symposiums and publishes research papers on various topics related to infection research. The company was founded in 2008, and the CEO is Ulrich Kalinke. | Commercial Services |
- Stock Market
- Insiders
- Ulrich Kalinke
- Experience